Major Depressive Disorder – Japan Drug Forecast and Market Assessment to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4995

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly’s Cymbalta and Otsuka/BMS’ Abilify have occurred, and recent launches of Lundbeck/Takeda’s Trintellix and Otsuka/Lundbeck’s Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards treatment-resistant patients, a significant unmet need. GlobalData estimated that MDD drug sales in Japan during 2015 reached $315.0m, making it the second largest single market in the 7MM. GlobalData estimates that the Japanese MDD market will be turbulent during the forecast period with important patent losses occurring, such as Otsuka/BMS’ Abilify, Eli Lilly’s Cymbalta, and Lundbeck/Allergan’s Lexapro. Effexor will see the highest growth rate of any drug in the Japanese MDD market over the 10-year forecast. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Overview of MDD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in Japan from 2015-2025.

Analysis of the impact of key events as well the drivers and restraints affecting Japan MDD market.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for MDD.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2015-2025 in Japan.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Related Reports

2.2Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.2Classification

3.3Symptoms and Subtypes of Major Depressive Disorder

3.4Prognosis

3.5Quality of Life

4Disease Management

4.1Diagnosis and Treatment Overview

4.1.1Diagnosis

4.1.2Treatment Guidelines

4.1.3Clinical Practice

4.2Japan

5Competitive Assessment

5.1Overview

5.2Selective Serotonin Reuptake Inhibitors

5.2.1Lexapro (Escitalopram)

5.2.2Viibryd (Vilazodone)

5.2.3Other Selective Serotonin Reuptake Inhibitors

5.3Serotonin-Norepinephrine Reuptake Inhibitors

5.3.1Cymbalta (Duloxetine)

5.3.2Effexor (Venlafaxine)

5.3.3Fetzima (Levomilnacipran)

5.3.4Savella (Milnacipran)

5.3.5Pristiq (Desvenlafaxine)

5.4Multimodal Antidepressants

5.4.1Trintellix (Vortioxetine)

5.5Other Antidepressants

5.5.1Bupropion

5.5.2Symbyax (Olanzapine/Fluoxetine)

5.5.3Mirtazapine

5.5.4Monoamine Oxidase Inhibitors

5.5.5Tricyclic Antidepressants

5.6Antipsychotics

5.6.1Abilify (Aripiprazole)

5.6.2Seroquel XR (Quetiapine XR)

5.6.3Rexulti (Brexpiprazole)

5.7Other Therapeutic Classes

6Unmet Need and Opportunity

6.1Overview

6.2New Therapies with Better Efficacy

6.2.1Unmet Need

6.2.2Gap Analysis

6.2.3Opportunity

6.3Improved Safety Profiles

6.3.1Unmet Need

6.3.2Gap Analysis

6.3.3Opportunity

6.4Rapid Onset of Action

6.4.1Unmet Need

6.4.2Gap Analysis

6.4.3Opportunity

6.5Personalized Treatment Approach

6.5.1Unmet Need

6.5.2Gap Analysis

6.5.3Opportunity

6.6Manage Patient Outcome Expectations

6.6.1Unmet Need

6.6.2Gap Analysis

6.6.3Opportunity

7Pipeline Assessment

7.1Overview

7.2Clinical Trial Mapping

7.2.1Clinical Trials by Class of Therapy

7.3Promising Drugs in Clinical Development

7.3.1ALKS-5461

7.3.2Vraylar (Cariprazine)

7.3.3ASC-01

7.3.4AXS-05

7.3.5Esketamine

7.3.6Rapastinel (GLYX-13)

7.3.7Strada (MSI-195)

7.3.8Viotra (Tramadol)

7.4Promising Drugs in Early-Stage Development

7.4.1CGP3466B

7.4.2NSI-189

7.5Other Drugs in Development

8Market Outlook

8.1Japan

8.1.1Forecast

8.1.2Key Events

8.1.3Drivers and Barriers

9Appendix

9.1Bibliography

9.2Abbreviations

9.3Methodology

9.4Forecasting Methodology

9.4.1Diagnosed NSCLC Patients

9.4.2Percent Drug-Treated Patients

9.4.3Drugs Included in Each Therapeutic Class

9.4.4Launch and Patent Expiry Dates

9.4.5General Pricing Assumptions

9.4.6Individual Drug Assumptions

9.4.7Generic Erosion

9.4.8Pricing of Pipeline Agents

9.5Primary Research – KOLs

9.5.1KOLs

9.6About the Authors

9.6.1Analyst

9.6.2Therapy Area Director

9.6.3Epidemiologist

9.6.4Global Head of Healthcare

9.7About GlobalData

9.8Disclaimer

Table

Table 1: Classification and Criteria of MDD (DSM-IV) and MDE (ICD-10)

Table 2: Subtypes of Major Depressive Disorder

Table 3: Severity of Depressive Episodes According to ICD-10 and DSM-IV Diagnostic Criteria

Table 4: Treatment Guidelines for Major Depressive Disorder

Table 5: Most-Prescribed Drugs for MDD by Class in the 7MM, 2015

Table 6: Country Profile – Japan

Table 7: Leading Treatments for MDD, 2016

Table 8: Product Profile – Lexapro

Table 9: Lexapro/Cipralex SWOT Analysis, 2016

Table 10: Product Profile – Viibryd

Table 11: Summary of Efficacy Results for the Primary Endpoint in Viibryd Clinical Trials

Table 12: Viibryd SWOT Analysis, 2016

Table 13: Summary of SSRIs, 2016

Table 14: SSRIs SWOT Analysis, 2016

Table 15: Product Profile – Cymbalta

Table 16: Cymbalta SWOT Analysis, 2016

Table 17: Product Profile – Effexor

Table 18: Effexor SWOT Analysis, 2016

Table 19: Product Profile – Fetzima

Table 20: Fetzima SWOT Analysis, 2016

Table 21: Product Profile – Savella

Table 22: Savella SWOT Analysis, 2016

Table 23: Product Profile – Pristiq

Table 24: Pristiq SWOT Analysis, 2016

Table 25: Product Profile – Trintellix

Table 26: Trintellix SWOT Analysis, 2016

Table 27: Product Profile – Bupropion

Table 28: Bupropion SWOT Analysis, 2016

Table 29: Product Profile – Symbyax

Table 30: Symbyax SWOT Analysis, 2016

Table 31: Product Profile – Mirtazapine

Table 32: Mirtazapine SWOT Analysis, 2016

Table 33: MAOIs SWOT Analysis, 2016

Table 34: TCAs SWOT Analysis, 2016

Table 35: Product Profile – Abilify

Table 36: Abilify SWOT Analysis, 2016

Table 37: Product Profile – Seroquel XR

Table 38: Seroquel XR SWOT Analysis, 2016

Table 39: Product Profile – Rexulti

Table 40: Rexulti SWOT Analysis, 2016

Table 41: Summary of Minor Therapeutic Classes in MDD, 2016

Table 42: Unmet Needs and Opportunities in MDD

Table 43: Promising Drugs in Clinical Development for MDD, 2016

Table 44: Comparison of Drugs in Development for MDD, 2016

Table 45: Product Profile – ALKS-5461

Table 46: SWOT Analysis – ALKS-5461, 2016

Table 47: Product Profile – Vraylar

Table 48: SWOT Analysis – Vraylar, 2016

Table 49: Product Profile – ASC-01

Table 50: SWOT Analysis – ASC-01, 2016

Table 51: Product Profile – AXS-05

Table 52: SWOT Analysis – AXS-05, 2016

Table 53: Product Profile – Esketamine

Table 54: SWOT Analysis – Esketamine, 2016

Table 55: Product Profile – Rapastinel

Table 56: SWOT Analysis – Rapastinel, 2016

Table 57: Product Profile – Strada

Table 58: SWOT Analysis – Strada, 2016

Table 59: Product Profile – Viotra

Table 60: SWOT Analysis – Viotra, 2015

Table 61: Drugs in Development, 2016

Table 62: Key Events Impacting Sales for MDD Therapies in Japan, 2015–2025

Table 63: MDD Market – Drivers and Barriers in Japan, 2015–2025

Table 64: Key Launch Dates – Part I

Table 65: Key Launch Dates – Part II

Table 66: Key Patent Expiries

Table 67 Average Body Weight and Surface Area Across the 8MM

Table 68: Average Cost of Therapy of Alimta in the 8MM

Table 69: Average Cost of Therapy of Alecensa in the 8MM

Table 70: Average Cost of Therapy of Avastin

Table 71: Average Cost of Therapy of Cyramza

Table 72: Average Cost of Therapy of Gilotrif

Table 73: Average Cost of Therapy of Iressa

Table 74: Average Cost of Therapy of Portrazza

Table 75: Average Cost of Therapy of Tagrisso

Table 76: Average Cost of Therapy of Tarceva

Table 77: Average Cost of Therapy of Vargatef

Table 78: Average Cost of Therapy of Xalkori

Table 79: Average Cost of Therapy of Zykadia

Table 80: Average Cost of Therapy of Keytruda

Table 81: Average Cost of Therapy of Opdivo

Table 82: Average Cost of Therapy of Tecentriq

Table 83: Average Cost of Therapy of Conmana

Table 84: High-Prescribing Physicians Surveyed by Country

Figures

Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons

Figure 2: Disease Management Model for Major Depressive Disorder

Figure 3: Major Depressive Disorder Treatment Algorithm

Figure 4: MDD Therapeutics – Phase II and III Clinical Trials in the 7MM, 2016

Figure 5: MDD Phase II/Phase III Pipeline, 2016

Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2015–2025

Figure 7: Clinical and Commercial Positioning of ALKS-5461

Figure 8: Clinical and Commercial Positioning of Vraylar

Figure 9: Clinical and Commercial Positioning of ASC-01

Figure 10: Clinical and Commercial Positioning of AXS-05

Figure 11: Clinical and Commercial Positioning of Esketamine

Figure 12: Clinical and Commercial Positioning of Rapastinel

Figure 13: Clinical and Commercial Positioning of Strada

Figure 14: Clinical and Commercial Positioning of Viotra

Figure 15: Japan Sales by Drug Class for MDD Therapies, 2015 and 2025

Figure 16: Japan Sales by Drug Class for MDD Therapies, 2015–2025

Frequently asked questions

Major Depressive Disorder – Japan Drug Forecast and Market Assessment to 2025 thematic reports
Currency USD
$4,995

Can be used by individual purchaser only

$14,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Major Depressive Disorder – Japan Drug Forecast and Market Assessment to 2025 in real time.

  • Access a live Major Depressive Disorder – Japan Drug Forecast and Market Assessment to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.